Use of clean technology in the national production of active principles with pharmacological activity

• Grant number: 99/11665-4
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: November 01, 2000
• End date: January 31, 2004
• Field of knowledge: Physical Sciences and Mathematics - Chemistry - Organic Chemistry
• Principal Investigator: Moacir de Mancilha
• Grantee: Moacir de Mancilha
• Company: Synthon Especialidades Químicas Ltda. - ME
• City: Sorocaba

Abstract

The treatment for pulmonary tuberculosis consists of the association of medication, good nutrition and rest. The first drugs used were streptomycin, isoniazid and para-aminosalicylic acid, all capable of eradicating the tuberculosis bacillus from the human organism. Other effective drugs are etambutol, rifampicin, thiacetazone and pirazinamid. Although the infection is halted quickly, the complete cure requires several months of treatment. Thus, it is of strategic importance that Brazil becomes self-sufficient in these medicines. The production of pirazinamid was discontinued in the country and, in the last 8 years around 79 tons of technical pirazinamid were imported, which signified a foreign exchange cost of US$ 3,333,678. The objectives of this project are: 1) the development of clean methodologies for the production of drugs for the treatment of tuberculosis (pirazinamid); 2) subsequent implementation on an industrial scale. The methodologies to be developed consist of: 3) studying the oxidization of quinoxalin 6 through the use of ozone with catalytic quantities of manganese dioxide, and 4) studying the synthesis of pirazinamid from 2,3-diamino-propionic acid 9. (AU)